VIR logo

VIR Vir Biotechnology Inc

$10.62
$0.10
(0.93%)
Today
57

Bullish Sentiment

How do you feel about VIR?

Loading...
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New...
Business Wire
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts...
Business Wire
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason OByrne is leaving the Company to pursue another opportunity and will remain with Vir...
Business Wire
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the...
Business Wire
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. We are pleased to welcome Tim to Vir Biotechnologys Board of Directors at a pivotal moment for the company, said Marianne...
Business Wire
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now...
Yahoo! Finance: News
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Key PointsSuperstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices...
Nasdaq News: Markets